NO313177B1 - Farmasöytisk blanding omfattende mirtazapin og ±n eller flere selektive serotonin-gjenopptaks-inhibitorer, anvendelse derav ogpakning - Google Patents

Farmasöytisk blanding omfattende mirtazapin og ±n eller flere selektive serotonin-gjenopptaks-inhibitorer, anvendelse derav ogpakning Download PDF

Info

Publication number: NO313177B1
Authority: NO; Norway
Prior art keywords: mirtazapine; ssris; pharmaceutically acceptable; fluoxetine; acceptable salt
Prior art date: 1996-06-19

Application number

NO19972816A

Other languages

English (en)

Norwegian (no)

Other versions

NO972816L (no

NO972816D0 (no

Inventor

Victor Johannes Nickolson

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-19

Filing date

1997-06-18

Publication date

2002-08-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO313177(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-18 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

1997-06-18 Publication of NO972816D0 publication Critical patent/NO972816D0/no

1997-12-22 Publication of NO972816L publication Critical patent/NO972816L/no

2002-08-26 Publication of NO313177B1 publication Critical patent/NO313177B1/no

Links

229940124834 selective serotonin reuptake inhibitor Drugs 0.000 title claims description 45
229960001785 mirtazapine Drugs 0.000 title claims description 43
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title claims description 43
239000012896 selective serotonin reuptake inhibitor Substances 0.000 title claims description 43
238000004806 packaging method and process Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
150000003839 salts Chemical class 0.000 claims description 24
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 23
229960002464 fluoxetine Drugs 0.000 claims description 23
238000002360 preparation method Methods 0.000 claims description 20
230000000694 effects Effects 0.000 claims description 15
239000000825 pharmaceutical preparation Substances 0.000 claims description 12
239000000935 antidepressant agent Substances 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 5
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 5
229960004038 fluvoxamine Drugs 0.000 claims description 5
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 5
229960002296 paroxetine Drugs 0.000 claims description 5
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 4
-1 cericlamin Chemical compound 0.000 claims description 4
229960001653 citalopram Drugs 0.000 claims description 4
229960002073 sertraline Drugs 0.000 claims description 4
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 4
208000020401 Depressive disease Diseases 0.000 claims description 3
230000001430 anti-depressive effect Effects 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 claims description 3
229950003930 femoxetine Drugs 0.000 claims description 3
229950006314 ifoxetine Drugs 0.000 claims description 3
ZHFIAFNZGWCLHU-YPMHNXCESA-N ifoxetine Chemical compound CC1=CC=CC(O[C@@H]2[C@@H](CNCC2)O)=C1C ZHFIAFNZGWCLHU-YPMHNXCESA-N 0.000 claims description 3
MJJDYOLPMGIWND-UHFFFAOYSA-N litoxetine Chemical compound C=1C=C2C=CC=CC2=CC=1COC1CCNCC1 MJJDYOLPMGIWND-UHFFFAOYSA-N 0.000 claims description 3
229950004138 litoxetine Drugs 0.000 claims description 3
229960002791 zimeldine Drugs 0.000 claims description 2
OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 claims description 2
239000004480 active ingredient Substances 0.000 description 12
239000003814 drug Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 11
241000700159 Rattus Species 0.000 description 9
230000037396 body weight Effects 0.000 description 8
150000001875 compounds Chemical class 0.000 description 7
238000000034 method Methods 0.000 description 7
239000000654 additive Substances 0.000 description 5
229940005513 antidepressants Drugs 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
230000036299 sexual function Effects 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000006187 pill Substances 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
230000004596 appetite loss Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000021266 loss of appetite Nutrition 0.000 description 2
208000019017 loss of appetite Diseases 0.000 description 2
230000008693 nausea Effects 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
108010009685 Cholinergic Receptors Proteins 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Chemical class 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000003001 depressive effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000000428 dust Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000003595 mist Substances 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
230000003982 neuronal uptake Effects 0.000 description 1
230000000966 norepinephrine reuptake Effects 0.000 description 1
230000012154 norepinephrine uptake Effects 0.000 description 1
229940053544 other antidepressants in atc Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000018052 penile erection Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
229940071981 sertraline 50 mg Drugs 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Chemical class 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19972816A 1996-06-19 1997-06-18 Farmasöytisk blanding omfattende mirtazapin og ±n eller flere selektive serotonin-gjenopptaks-inhibitorer, anvendelse derav ogpakning NO313177B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP96201703		1996-06-19

Publications (3)

Publication Number	Publication Date
NO972816D0 NO972816D0 (no)	1997-06-18
NO972816L NO972816L (no)	1997-12-22
NO313177B1 true NO313177B1 (no)	2002-08-26

Family

ID=8224094

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19972816A NO313177B1 (no)	1996-06-19	1997-06-18	Farmasöytisk blanding omfattende mirtazapin og ±n eller flere selektive serotonin-gjenopptaks-inhibitorer, anvendelse derav ogpakning

Country Status (24)

Country	Link
US (1)	US5977099A (fr)
JP (2)	JP4925074B2 (fr)
KR (1)	KR100481254B1 (fr)
CN (1)	CN1132581C (fr)
AR (1)	AR007609A1 (fr)
AT (1)	ATE213159T1 (fr)
AU (1)	AU727851B2 (fr)
BR (1)	BR9703624A (fr)
CA (1)	CA2208199C (fr)
CZ (1)	CZ290691B6 (fr)
DE (1)	DE69710390T2 (fr)
DK (1)	DK0813873T3 (fr)
ES (1)	ES2172744T3 (fr)
HU (1)	HU225534B1 (fr)
ID (1)	ID17051A (fr)
IL (1)	IL121076A (fr)
NO (1)	NO313177B1 (fr)
NZ (1)	NZ328113A (fr)
PL (1)	PL188520B1 (fr)
PT (1)	PT813873E (fr)
RU (1)	RU2181287C2 (fr)
SG (1)	SG60073A1 (fr)
TR (1)	TR199700522A2 (fr)
ZA (1)	ZA975335B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL121076A (en) *	1996-06-19	2000-10-31	Akzo Nobel Nv	Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
DK1030667T3 (da) *	1997-11-14	2005-06-20	Akzo Nobel Nv	Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö
US6960577B2 (en) *	1998-05-22	2005-11-01	Eli Lilly And Company	Combination therapy for treatment of refractory depression
US6727283B2 (en)	1998-10-13	2004-04-27	Pfizer Inc.	Sertraline oral concentrate
US6575147B2 (en) *	1999-02-25	2003-06-10	Go-Tec	Internal combustion system adapted for use of a dual fuel composition including acetylene
AU781221B2 (en) *	1999-04-19	2005-05-12	Teva Pharmaceutical Industries Ltd.	Novel synthesis and crystallization of piperazine ring-containing compounds
US6545149B2 (en)	1999-04-19	2003-04-08	Teva Pharmaceutical Industries Ltd.	Synthesis and crystallization of piperazine ring-containing compounds
US6759437B2 (en) *	1999-10-04	2004-07-06	Martin C. Hinz	Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) *	1999-10-04	2002-06-11	Martin C. Hinz	Comprehensive pharmacologic therapy for treatment of obesity
TWI256309B (en) *	1999-10-13	2006-06-11	Akzo Nobel Nv	New formulation of mirtazapine
CA2396066A1 (fr) *	2000-01-19	2001-07-26	Akzo Nobel N.V.	Association de medicaments pour le traitement de depressions et de troubles s'y rapportant, comprenant de la mirtazapine
IL150290A0 (en) *	2000-02-11	2002-12-01	Akzo Nobel Nv	The use of mirtazapine for the treatment of sleep disorders
WO2002036113A1 (fr) *	2000-11-01	2002-05-10	Respiratorius Ab	Composition comprenant des agonistes (5ht-4) et des antagonistes (5ht-2, 5ht-3) recepteurs de la serotonine
WO2002064735A2 (fr) *	2001-02-12	2002-08-22	Akzo Nobel N.V.	Methodes permettant d'ameliorer le traitement de depressions graves par genotypage visant a determiner le gene associe a l'apolipoproteine e4 et d'ameliorer la reponse therapeutique de personnes souffrant de depression grave et porteuses du gene associe a l'apolipoproteine e4
US6399310B1 (en)	2001-02-12	2002-06-04	Akzo Nobel N.V.	Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) *	2001-12-03	2003-06-05	Murphy Greer Marechal	Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20090311795A1 (en) *	2002-03-21	2009-12-17	Hinz Martin C	Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) *	2006-06-08	2007-12-20	Hinz Martin C	Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
BR0308556A (pt) *	2002-03-21	2005-05-03	Martin C Hinnz	Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas
PL376832A1 (pl) *	2002-11-07	2006-01-09	Torrent Pharmaceuticals Ltd.	Sposób wytwarzania polimorficznej postaci chlorowodorku sertraliny
NZ556779A (en)	2002-12-27	2008-12-24	Otsuka Pharma Co Ltd	Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) *	2002-12-27	2005-07-06	Otsuka Pharma Co Ltd	Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05008943A (es) *	2003-02-21	2005-11-08	C Hinz Martin	Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina.
TW200502222A (en) *	2003-04-02	2005-01-16	Novartis Ag	Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004096201A1 (fr)	2003-04-29	2004-11-11	Orexigen Therapeutics, Inc.	Compositions influant sur la perte de poids
US20050234093A1 (en) *	2003-06-25	2005-10-20	H. Lundbeck A/S	Treatment of depression and other affective disorders
US7838029B1 (en)	2003-07-31	2010-11-23	Watson Laboratories, Inc.	Mirtazapine solid dosage forms
US7390503B1 (en)	2003-08-22	2008-06-24	Barr Laboratories, Inc.	Ondansetron orally disintegrating tablets
EP1667972B1 (fr)	2003-09-10	2013-06-19	Brentwood Equities Ltd.	Diastereoisomeres de 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) *	2004-04-21	2005-12-01	Akzo Nobel Nv	Mirtazapine salts
US20060039866A1 (en) *	2004-08-20	2006-02-23	Cypress Bioscience, Inc.	Method for treating sleep-related breathing disorders
RU2283097C2 (ru) *	2004-11-16	2006-09-10	Эльвира Ивановна Белобородова	Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
EP1827450A4 (fr) *	2004-11-17	2009-04-22	Cypress Bioscience Inc	Methodes servant a limiter les effets secondaires d'un traitement par mirtazapine
CN101060860B (zh) *	2004-11-19	2013-07-17	Msd欧斯股份有限公司	用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合
ES2761812T3 (es)	2005-11-22	2020-05-21	Nalpropion Pharmaceuticals Inc	Composición y métodos de aumento de la sensibilidad a la insulina
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
DK2089005T3 (da)	2006-11-09	2010-07-19	Orexigen Therapeutics Inc	Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20150082689A (ko)	2006-11-09	2015-07-15	오렉시젠 세러퓨틱스 인크.	단위 용량 팩키지
EP2167096A4 (fr) *	2007-06-13	2010-07-14	Cypress Bioscience Inc	Amélioration de la tolérance à la mirtazapine et à un second principe actif par utilisation combinée de ces derniers
CN101332193B (zh) *	2007-06-29	2012-12-12	杭州民生药业有限公司	一种马来酸氟伏沙明药物组合物的制备方法
WO2009158114A1 (fr)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Procédés pour traiter des pathologies des graisses viscérales
US8768578B2 (en)	2009-06-09	2014-07-01	Sumitomo Heavy Industries, Ltd.	Hybrid excavator and method of controlling hybrid excavator
WO2011059207A2 (fr) *	2009-11-13	2011-05-19	Green Cross Corporation	Dérivés de purine contenant une arylpipérazine et leurs applications
CN102724878A (zh)	2010-01-11	2012-10-10	奥雷西根治疗公司	在重度抑郁症患者中提供体重减轻疗法的方法
CN102000334B (zh) *	2010-10-15	2012-02-22	北京大学	用于治疗抑郁症的复方制剂
RU2475235C2 (ru) *	2011-03-15	2013-02-20	Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА"	Фармацевтическая композиция для профилактики и лечения депрессивных состояний
JOP20120083B1 (ar) *	2011-04-05	2021-08-17	Otsuka Pharma Co Ltd	توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
HUE072188T2 (hu)	2012-06-06	2025-10-28	Nalpropion Pharmaceuticals Llc	Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL189199C (nl) *	1975-04-05	1993-02-01	Akzo Nv	Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) *	1981-08-27	1983-03-03	Shaun R. Coughlin	Composition for the treatment of atherosclerosis
US4940585A (en) *	1989-02-17	1990-07-10	Hapworth William E	Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) *	1989-12-06	1993-05-04	Akzo N.V.	Stabilized solutions of psychotropic agents
DK0431663T3 (da) *	1989-12-06	1994-03-07	Akzo Nobel Nv	Stabiliserende opløsninger af psykotrope midler
IE63986B1 (en) *	1989-12-30	1995-06-28	Akzo Nv	Pharmaceutical preparation for oral administration in fluid form
US5512593A (en) *	1993-03-02	1996-04-30	John S. Nagle	Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) *	1996-06-19	2000-10-31	Akzo Nobel Nv	Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) *	1997-03-27	2004-05-21	Akzo Nobel Nv	Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
ATE232384T1 (de) *	1997-10-03	2003-02-15	Cary Medical Corp	Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion

1997
- 1997-06-13 IL IL12107697A patent/IL121076A/xx not_active IP Right Cessation
- 1997-06-16 US US08/876,346 patent/US5977099A/en not_active Expired - Fee Related
- 1997-06-16 SG SG1997002068A patent/SG60073A1/en unknown
- 1997-06-17 ES ES97201853T patent/ES2172744T3/es not_active Expired - Lifetime
- 1997-06-17 PT PT97201853T patent/PT813873E/pt unknown
- 1997-06-17 ZA ZA9705335A patent/ZA975335B/xx unknown
- 1997-06-17 AT AT97201853T patent/ATE213159T1/de not_active IP Right Cessation
- 1997-06-17 NZ NZ328113A patent/NZ328113A/en unknown
- 1997-06-17 CZ CZ19971870A patent/CZ290691B6/cs not_active IP Right Cessation
- 1997-06-17 DE DE69710390T patent/DE69710390T2/de not_active Expired - Fee Related
- 1997-06-17 DK DK97201853T patent/DK0813873T3/da active
- 1997-06-18 RU RU97110083/14A patent/RU2181287C2/ru not_active IP Right Cessation
- 1997-06-18 NO NO19972816A patent/NO313177B1/no unknown
- 1997-06-18 HU HU9701068A patent/HU225534B1/hu not_active IP Right Cessation
- 1997-06-18 BR BR9703624A patent/BR9703624A/pt not_active Application Discontinuation
- 1997-06-18 CA CA002208199A patent/CA2208199C/fr not_active Expired - Fee Related
- 1997-06-18 PL PL97320628A patent/PL188520B1/pl not_active IP Right Cessation
- 1997-06-18 KR KR1019970025307A patent/KR100481254B1/ko not_active Expired - Fee Related
- 1997-06-19 ID IDP972117A patent/ID17051A/id unknown
- 1997-06-19 AR ARP970102687A patent/AR007609A1/es active IP Right Grant
- 1997-06-19 JP JP16257697A patent/JP4925074B2/ja not_active Expired - Fee Related
- 1997-06-19 AU AU26129/97A patent/AU727851B2/en not_active Ceased
- 1997-06-19 TR TR97/00522A patent/TR199700522A2/xx unknown
- 1997-06-19 CN CN97115549A patent/CN1132581C/zh not_active Expired - Fee Related
2008
- 2008-12-12 JP JP2008317326A patent/JP2009137970A/ja active Pending

Also Published As

Publication number	Publication date
PT813873E (pt)	2002-06-28
KR980000447A (ko)	1998-03-30
HUP9701068A3 (en)	2000-07-28
SG60073A1 (en)	1999-02-22
KR100481254B1 (ko)	2005-09-12
DE69710390D1 (de)	2002-03-21
NO972816L (no)	1997-12-22
TR199700522A3 (tr)	1998-01-21
ID17051A (id)	1997-12-04
US5977099A (en)	1999-11-02
HK1006081A1 (en)	1999-02-12
JP2009137970A (ja)	2009-06-25
HUP9701068A2 (hu)	1998-08-28
CZ290691B6 (cs)	2002-09-11
DE69710390T2 (de)	2002-08-14
CZ187097A3 (cs)	1998-01-14
JP4925074B2 (ja)	2012-04-25
JPH1067663A (ja)	1998-03-10
CN1132581C (zh)	2003-12-31
ZA975335B (en)	1998-01-26
BR9703624A (pt)	1998-09-01
NZ328113A (en)	1999-09-29
PL320628A1 (en)	1997-12-22
HU9701068D0 (en)	1997-08-28
AU2612997A (en)	1998-01-08
ATE213159T1 (de)	2002-02-15
PL188520B1 (pl)	2005-02-28
CA2208199A1 (fr)	1997-12-19
NO972816D0 (no)	1997-06-18
AU727851B2 (en)	2001-01-04
IL121076A (en)	2000-10-31
TR199700522A2 (xx)	1998-01-21
RU2181287C2 (ru)	2002-04-20
HU225534B1 (en)	2007-02-28
IL121076A0 (en)	1997-11-20
MX9704579A (es)	1998-07-31
DK0813873T3 (da)	2002-05-27
ES2172744T3 (es)	2002-10-01
CN1173330A (zh)	1998-02-18
AR007609A1 (es)	1999-11-10
CA2208199C (fr)	2006-10-24

Publication	Publication Date	Title
AU727851B2 (en)	2001-01-04	Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US20080004338A1 (en)	2008-01-03	Use of enantiomeric pure escitalopram
US20040029941A1 (en)	2004-02-12	Zonisamide use in obesity and eating disorders
US20090018205A1 (en)	2009-01-15	Methods for treatment of migraine and symptoms thereof
US12377064B2 (en)	2025-08-05	Treatment of moderate and severe gastroparesis
US10576045B2 (en)	2020-03-03	Low dosage combinations of fluoxetine and reboxetine for treating obesity
EP0813873B1 (fr)	2002-02-13	Compositions pharmaceutiques comprenants de la mirtazapine et un ou plusieurs inhibiteurs sélectifs d'assimilation de sérotonine
CZ301210B6 (cs)	2009-12-09	Použití desoxypeganinu k ošetrování klinické deprese
AU2345192A (en)	1994-02-14	Use of 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone in the treatment of angina pectoris
KR20010105418A (ko)	2001-11-28	기분 장애 치료용 오사네턴트
MXPA97004579A (en)	1998-11-09	Pharmaceutical composition comprising mirtazapine and one or more selective seroton reabsorption inhibitors
CN107952075A (zh)	2018-04-24	一种含大麻二酚的组合物及其应用
HK1006081B (en)	2002-05-31	Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
WO2000006140A2 (fr)	2000-02-10	Procedes et compositions permettant de traiter et de prevenir certains troubles psychiatriques et medicaux par le moclobemide
AU616249B2 (en)	1991-10-24	Antihypertensive combination
JP2005500344A (ja)	2005-01-06	３−アリールオキシ−３−フェニルプロパンアミンを用いた慢性疼痛の治療
HK1078778A (en)	2006-03-24	Use of reboxetine for the treatment of hot flashes
EA028400B1 (ru)	2017-11-30	Способ профилактики и лечения ожирения и избыточного веса и связанных с ними нарушений